[{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"1cb3a87f-6700-43c5-97eb-2ad01d3c6932","acronym":"","url":"https://clinicaltrials.gov/study/NCT02799485","created_at":"2021-01-18T13:44:04.096Z","updated_at":"2024-07-02T16:35:44.581Z","phase":"Phase 2","brief_title":"sEphB4-HSA in Treating Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT02799485","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" EPHB4","pipe":"","alterations":" ","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sEphB4-HSA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-06-27"},{"id":"39e77f40-8915-4aeb-9493-f54c50c8da6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05502458","created_at":"2022-08-16T11:56:13.589Z","updated_at":"2024-07-02T16:36:05.399Z","phase":"Phase 2","brief_title":"Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor","source_id_and_acronym":"NCT05502458","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • ELF3 • EPHB4 • GAPDH","pipe":"","alterations":" ","tags":["EGFR • ELF3 • EPHB4 • GAPDH"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 08/08/2022","primary_completion_date":" 08/08/2022","study_txt":" Completion: 08/08/2022","study_completion_date":" 08/08/2022","last_update_posted":"2022-08-16"}]